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Abstract
Background: Healthcare-associated infection (HAI) is a major challenge for patient safety worldwide, and is further
complicated by antimicrobial resistance (AMR) due to excessive antimicrobial use in both humans and animals.
Existing infection prevention and control (IPC) networks must be strengthened and adapted to better address the
global challenges presented by emerging AMR.
Methods: In June 2017, 42 international experts convened in Geneva, Switzerland, to discuss two key areas for
strengthening the global IPC network: 1) broadening collaboration in IPC; and 2) how to bring the fields IPC and
AMR control together.
Results: The US Centers for Disease Prevention and Control, the European Centre for Disease Prevention and
Control, and the World Health Organization (WHO) convened together with international experts to discuss
collaboration and networks, demonstrating the participating organizations’ commitment to close collaboration in
IPC. The challenge of emerging AMR can only be addressed by strengthening this collaboration across international
organisations and between public health and academia. The WHO SAVE LIVES: Clean Your Hands initiative is an
example of a successful collaboration between multiple global stakeholders including academia and international
public health organisations; it can be used as a model. IPC-strategies are included within the four pillars to combat
AMR: surveillance, IPC, antimicrobial and diagnostic stewardship, research and development. The prevention of
transmission of multidrug-resistant microorganisms is a patient safety issue, and must be strengthened in the fight
against AMR.
Conclusions: The working group determined that international organisations should take the lead in creating new
networks, which will in turn attract academia and other stakeholders to join. At the same time, they should invest
in bringing existing IPC and AMR networks under one umbrella. Transmission of multidrug-resistant microorganisms
in hospitals and in the community threatens the success of antimicrobial stewardship programmes, and thus,
research and development in IPC should be addressed as an enhanced global priority.
Keywords: Networks, Collaboration, Infection prevention and control, International, National, Institutional, Change,
CDC, ECDC, WHO
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: Walter.Zingg@hcuge.ch; walter.zingg@hcuge.ch
1Infection control programme and WHO collaborating center, University of
Geneva Hospitals and Faculty of Medicine, 4 Rue Gabrielle Perret-Gentil, 1211
Geneva 14, Switzerland
Full list of author information is available at the end of the article
Zingg et al. Antimicrobial Resistance and Infection Control            (2019) 8:74 
https://doi.org/10.1186/s13756-019-0528-0
Background
Under the auspices of the US Centers for Disease Control
and Prevention (CDC), the World Health Organization
(WHO), and the University of Geneva Hospitals and
Faculty of Medicine (HUG), an international panel of 42
experts with backgrounds in infection prevention and
control (IPC), microbiology, infectious diseases, public
health, psychology, medical technology, and social sci-
ences, convened for 2 days at the Geneva Think Tank on
IPC and antimicrobial resistance (AMR) in June 2017.
The aim was to develop a global vision on IPC and AMR,
and to agree on a road map for research and public health
activities. Three dimensions of IPC and AMR were dis-
cussed: 1) implementation of IPC and antimicrobial stew-
ardship; 2) technology in IPC and AMR; and 3)
broadening the global IPC network. This is the final paper
in a series of three summarising the discussions during
the meeting, and addressing the current and future role of
networks in IPC.
Methods
Two key areas for strengthening the IPC networks glo-
bally were addressed: 1) broadening collaboration among
IPC organisations around the world; and 2) improving
and aligning IPC and AMR control efforts. Two impulse
talks for each of the areas set the stage for a moderated
plenary discussion. Writers took notes. This paper is the
summary of presentations and notes taken from the
plenary discussion.
Results
CDC, the European Centre for Disease Prevention and
Control (ECDC), and the WHO convened together and
with international experts to exchange their visions
about collaboration and networking, and demonstrated
their commitment for close collaboration in IPC.
Broadening the collaboration in infection prevention and
control and antimicrobial resistance
A number of international IPC and AMR networks are
already in place (Table 1). The WHO Global IPC Net-
work brings together major international and national
IPC organisations and in 2017, issued a call to action re-
lated to the global and national IPC priorities for 2018–
2022 [1]. Pre-existing surveillance modules on AMR,
antimicrobial consumption, and HAI surveillance in Europe
have been integrated to become the ECDC ARHAI-Net
(Antimicrobial resistance and healthcare-associated infection
network). This network collaborates with a number of other
networks. The Trans-Atlantic Task Force for Antimicrobial
Resistance (TATFAR) is an example of a transatlantic collab-
oration between a number of European and US members
(Table 1). The initiative agreed on 17 recommendations in 3
key areas: appropriate therapeutic use of antimicrobial drugs
in medical and veterinary communities; prevention of dru-
g-resistant infections; strategies for improving the pipeline
of new antimicrobial drugs and diagnostic devices, and
maintaining existing drugs on the market. There was con-
sensus in the group that the natural stakeholders for inter-
national collaboration are CDC, ECDC, and WHO,
although other regional or global organisations should
also be engaged. These public health organisations work
on the political level, cascading ideas and policies down to
ministries of health.
Experts in IPC and professional societies may not have a
public health perspective, but the role they play in driving
innovation and generating ideas and solutions cannot be
dismissed given the impact of such efforts on future public
health decision making. Ideally, expert-to-expert collabor-
ation would include international public health bodies.
Any resulting innovations would be more likely to incorp-
orate global or higher-level policy perspectives, with the
potential impact extending beyond research to become
standard in patient care. The WHO SAVE LIVES: Clean
Your Hands campaign exemplifies the success of such col-
laboration, where the campaign principle is that public
health and IPC experts work hand-in-hand to drive im-
provement [2]. In addition, the WHO hand hygiene cam-
paign benefits from the collaboration of a public-private
partnership, developed under the umbrella of the WHO
Private Organizations for Patient Safety (POPS)-Hand Hy-
giene. This collaboration, among others, enables campaign
messaging to be spread at the bedside in many countries,
using multiple languages, and adapting to different cul-
tural and resource needs [2]. Through its collaborating
centres, WHO has further strengthened the network be-
tween public health and academic institutions. The inte-
gration of Improving Patient Safety in Europe (IPSE),
European Surveillance of Antimicrobial Consumption
(ESAC), and European Antimicrobial Resistance Surveil-
lance System (EARSS) under the umbrella of ECDC’s
ARHAI-Net is another example of successfully transform-
ing academic work into a large scale public health initia-
tive. Examples from CDC’s numerous collaborations with
academia include the Prevention EpiCenters and the
Emerging Infections Program (EIP). There is little collabor-
ation of the many private initiatives in IPC and AMR. As
partners, international organisations can streamline and le-
verage the effect of such activities.
A challenge is the fact that research, and consequently
the guidance based on scientific findings, is typically
generated in high income countries. More research in
low-and-middle-income countries (LMICs) is needed,
but until this is available, at a minimum, the applicability
of recommendations to LMIC contexts should be
assessed. The WHO core components for IPC are a
good example of guidelines based on data primarily from
high income settings that have been integrated with
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Table 1 Collaborative networks in infection prevention and control and antimicrobial resistance on national and international levels
Acronym Network Lead Description/Mission Links
ARHAI-
Net
Antimicrobial Resistance
and Healthcare-Associated
Infections Network
ECDC Focus on surveillance, scientific advice, training and
communication to address the threat of antimicrobial
resistance and healthcare-associated infections.
ARHAI integrated the former European programmes
ESAC on antimicrobial consumption, EARSS on
antimicrobial resistance, HELICS on healthcare-
associated infections (surgical site infections; HAI in in-
tensive care), and IPSE on a wider patient safety
context.
https://ecdc.europa.eu/en/about-us/who-we-
are/disease-programmes/antimicrobial-
resistance-and-healthcare-associated
EIP Emerging Infections
Program
US-
CDC
Prevention and control of infectious diseases by
providing scientific information to monitor emergency
problems, evaluate public health interventions, and
inform policy.
https://www.cdc.gov/ncezid/dpei/eip/index.
html
IMI Innovative Medicines
Initiative
EC &
EFPIA
Working group on accelerating development and
access to innovative medicines, particularly in areas
where there is an unmet need.
IMI is the world’s biggest public-private partnership in
life sciences.
https://www.imi.europa.eu/about-imi/
mission-objectives
GIPCN Global Infection
Prevention and Control
Network
WHO GIPCN aims to enhance local, national and international
coordination and collaboration in the field of IPC and
to support WHO’s and countries’ efforts on IPC, from
preparedness, to IPC systems and programmes’
strengthening, outbreak prevention and control, as well
as capacity building for surveillance.
http://www.who.int/infection-prevention/
about/GIPC_Network/en/
GLASS Global Antimicrobial
Resistance Surveillance
System
WHO GLASS promotes and supports a standardized approach
to the collection, analysis and sharing of AMR data at a
global level by encouraging and facilitating the
establishment of national AMR surveillance systems that
are capable of monitoring AMR trends and producing
reliable and comparable data.
https://www.who.int/glass/partnerships/en/
JPIAMR Joint Programming
Initiative on Antimicrobial
Resistance
EU Basic and exploratory research on new antibiotics,
stewardship of existing antibiotics, and control of the
spread of antibiotic resistance between humans,
animals, and the environment in a One Health
perspective (26 countries globally).
https://www.jpiamr.eu/
POPS Private Organizations for
Patient Safety
WHO Public-private partnership to harness industry strengths
to align and improve implementation of WHO
recommendations in different parts of the world.
http://www.who.int/infection-prevention/
about/pops/en/
TATFAR Trans-Atlantic Force for
Antimicrobial Resistance
US-
CDC
Transatlantic collaboration between US-CDC, ECDC, EC,
EFSA, FDA, AMA, OGHA, and USDHS.
Improving appropriate therapeutic use of antimicrobial
drugs in medical and veterinary communities;
preventing healthcare- and community-associated
drug-resistant infections, and developing strategies for
improving the pipeline of new antimicrobial drugs.
https://www.cdc.gov/drugresistance/tatfar/
index.html
Antibiotic Resistance
Solutions Initiative
US-
CDC
The initiative invests in national infrastructure to detect,
respond, contain, and prevent resistant infections across
healthcare settings, food, and communities. CDC
funding supports all 50 state health departments, six
local health departments, and Puerto Rico.
https://www.cdc.gov/drugresistance/
solutions-initiative/index.html
Prevention EpiCenters US-
CDC
Collaborative research programme between the CDC’s
division of healthcare quality promotion and academic
investigators for conducting innovative infection
prevention and control research.
https://www.cdc.gov/hai/epicenters/index.
html
WHO SAVE LIVES: Clean
Your Hands
WHO WHO’s global annual campaign making a call to action
for health workers every 5 May concerning preventing
HAI through hand hygiene and IPC improvements .
http://www.who.int/infection-prevention/
campaigns/clean-hands/en/
AMA American Medical Association, EARSS European Antimicrobial Resistance Surveillance System, EC European Commission, EFPIA European Federation of
Pharmaceutical Industries and Associations, EFSA European Food Safety Authority, ESAC European Surveillance on Antimicrobial Consumption, EU European Union,
FDA US Food and Drug Association, HAI Healthcare-associated infection, HELICS Hospitals in Europe Link for Infection Control through Surveillance, IPSE Improving
Patient Safety in Europe, NIH US National Institutes of Health, OGHA Office of Global Health Affairs, US-CDC US Centers for Disease Control and Prevention, USDHS
US Department of Homeland Security, WHO World Health Organization
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experience and additional evidence from the field gath-
ered in LMIC settings according to a solid methodology.
In collaboration with CDC, WHO has developed imple-
mentation tools with special focus on low resource set-
tings, to support the adaptation and adoption of the
guidelines into the local context [3, 4]. These are exam-
ples on how international organisations can fill their role
as trusted promoters in improving the implementation
of IPC and AMR control in LMIC.
How to bring IPC and antimicrobial resistance control
together
Emerging AMR is a global problem, which can only be
controlled if stakeholders are working together at an
international level. AMR control relies on four pillars: 1)
surveillance (of infections, resistance and antimicrobial
use); 2) IPC (prevention of AMR transmission); 3) anti-
microbial stewardship; and 4) research and development.
It is well accepted that all four pillars are needed to both
define the problem (research, surveillance), and to solve
it (IPC, antimicrobial stewardship).
Preventing the spread of multidrug-resistant organ-
isms depends predominantly on good IPC practice in
healthcare facilities, particularly hand hygiene, institu-
tional environmental cleaning, and isolation precaution
measures. Prevention of spread in the community set-
ting is also predicated on the existence of adequate
water, sanitation and hygiene measures. Additional mea-
sures include screening of patients at risk for carriage of
multi-resistant organisms according to defined strategies
that are adapted to individual types of AMR-pathogen
combinations. There is sufficient evidence that such
strategies work, the recommended actions are
straight-forward, and they can be applied immediately. If
cross-transmission is not contained, other AMR strat-
egies such as antimicrobial stewardship or the develop-
ment of new antimicrobials will be very limited in both
effect and sustained impact.
IPC as a core prevention measure has neither been
sufficiently recognized nor prioritized at the global level
to adequately address the scope of the AMR problem.
The field of IPC is not adequately interconnected with
the AMR community. This dichotomy is rooted in his-
tory. Research in AMR is infectious diseases and
microbiology-driven, often focusing on resistance mech-
anisms and genetic relatedness. Infection prevention and
control has a more practical attitude focusing on the
prevention of cross-transmission by promoting best
practice procedures. Scope and professional back-
grounds of stakeholders in IPC and AMR are often dif-
ferent. However, the need for collaboration between the
two has become more urgent. International organisations
such as CDC, ECDC, and WHO could take a lead on
bridging the gap between IPC and AMR experts. ECDCs
ARHAI network and CDC’s Antibiotic Resistance Solutions
Initiative are examples where activities on AMR and IPC
are under the same umbrella.
Discussion
International organisations should take the lead in both
strengthening existing and creating new networks, which
will attract academia and other stakeholders to join. At
the same time, they should invest in bringing existing
IPC and AMR networks under one umbrella. Transmis-
sion of multidrug-resistant microorganisms in hospitals
and in the community threatens successful combating of
AMR, and thus, measures to interrupt transmission i.e.
effective IPC strategies and programmes supported by
effective international and national networks should be
given more priority globally.
Conclusion
The working group determined that international orga-
nisations should take the lead in creating new networks,
and invest in bringing existing IPC and AMR networks
under one umbrella. Research and development in IPC
should be addressed as an enhanced global priority.
Abbreviations
AMA: American Medical Association; AMR: Antimicrobial resistance;
ARHAI: Antimicrobial Resistance and Healthcare-Associated Infection (−net-
work); CDC: US Centers for Disease Control and Prevention; EARSS: European
Antimicrobial Resistance Surveillance System; EC: European Commission;
ECDC: European Centre for Disease Prevention and Control; EFPIA: European
Federation of Pharmaceutical Industries and Associations; EFSA: European
Food Safety Authority; EIP: (CDC) Emerging Infections Program;
ESAC: European Surveillance on Antimicrobial Consumption; EU: European
Union; FDA: US Food and Drug Association; HAI: Healthcare-associated
infection; HELICS: Hospitals in Europe Link for Infection Control through
Surveillance; HUG: University of Geneva Hospitals; IMI: Innovative Medicines
Initiative; IPC: Infection prevention and control; IPSE: Improving Patient Safety
in Europe; JPIAMR: Joint Programming Initiative on Antimicrobial Resistance;
LMIC: Low-and-middle-income country; NIH: US National Institutes of Health;
OGHA: Office of Global Health Affairs; POPS: Private Organizations for Patient
Safety; TATFAR: Trans-Atlantic Task Force on Antimicrobial Resistance;
USDHS: US Department of Homeland Security; WHO: World Health
Organization
Acknowledgments
We would like to thank Mirko Saam and Derek Christie for taking notes; and
Alexandra Peters for editing.
The 2017 Geneva IPC-Think Tank: Mohamed Abbas; Raheelah Ahmad;
Benedetta Allegranzi; Antoine Andremont; Mike Bell; Michael Borg; Denise
Cardo; Yehuda Carmeli; Enrique Castro-Sanchez; John Conly; Philippe Eggi-
mann; Petra Gastmeier; M. Lindsay Grayson; Stephan Harbarth; Marcela Her-
nandez; Loreen Herwaldt; Alison Holmes; John A. Jernigan; Claire Kilpatrick;
Amy Kolwaite; Karl-Heinz Krause; Elaine Larson; Sarah Masson-Roy; Shaheen
Mehtar; Marc Mendelson; Ling Moi Lin; Andreea Moldovan; Dominique Mon-
net; Babacar Ndoye; Peter Nthumba; Folasade Ogunsola; Ben Park; Eli Peren-
cevich; Didier Pittet; Matthew Samore; Wing Hong Seto; Arjun Srinivasan;
Julie Storr; Evelina Tacconelli; Carolyn Tarrant; Sara Tomczyk; Maha Talaat; Maria
Virginia Villegas; Andreas Voss; Tim Walsh; Andreas Widmer; Walter Zingg.
Funding
The 2017 Geneva IPC-Think Tank was supported by the US Centers for Disease
Prevention and Control, and the University of Geneva Hospitals, Switzerland.
Zingg et al. Antimicrobial Resistance and Infection Control            (2019) 8:74 Page 4 of 5
Availability of data and materials
Not applicable.
Disclaimer
The authors alone are responsible for the views expressed in this article and
they do not necessarily represent the views, decisions or policies of the
institutions with which they are affiliated.
US CDC disclaimer
The findings and conclusions in this report are those of the authors and do
not necessarily represent the official position of CDC.
WHO disclaimer
The authors alone are responsible for the views expressed in this article and
they do not necessarily represent the views, decisions or policies of the
institutions with which they are affiliated.
Authors’ contributions
WZ, BP, JJ, DC, and DP organised the think tank. All authors contributed to
conducting this dimension of the think tank. WZ wrote the first draft of the
manuscript. WZ, JS, BP, JJ, SH, MLG, ET, BA, DC, and DP reviewed and
contributed to subsequent drafts. All authors approved the final version for
publication.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Infection control programme and WHO collaborating center, University of
Geneva Hospitals and Faculty of Medicine, 4 Rue Gabrielle Perret-Gentil, 1211
Geneva 14, Switzerland. 2Infection Prevention and Control Global Unit, World
Health Organization, Geneva, Switzerland. 3US Centers for Disease Control
and Prevention, Atlanta, GA, USA. 4Infectious Diseases Department, Austin
Health, University of Melbourne, Heidelberg, Victoria, Australia. 5Infectious
diseases unit, University Hospital Tübingen, Tübingen, Germany. 6Department
of diagnostics and public health, University of Verona, Verona, Italy.
Received: 18 February 2019 Accepted: 23 April 2019
References
1. Allegranzi B, Kilpatrick C, Storr J, Kelley E, Park BJ, Donaldson L. Global
infection prevention and control priorities 2018-22: a call for action. Lancet
Global Health. 2017;5:e1178–80.
2. Kilpatrick C, Storr J, Allegranzi B. A worldwide WHO hand hygiene in
healthcare campaign. In: Hand hygiene: a handbook for medical
professionals. Edited by Pittet D, Boyce JM, Allegranzi B. Chichester, West
Sussex: Wyley, Blackwell; 2017.
3. World Health Organization. Interim practical manual supporting national
implementation of the WHO guidelines on Core components of infection
prevention and control Programmes. Geneva: World Health Organization;
2017. Available at: https://www.who.int/infection-prevention/tools/core-
components/cc-implementation-guideline.pdf?ua=1. Accessed 12 Feb 2019
4. World Health Organization. Improving infection prevention and control at
the health facility: interim practical manual supporting implementation of
the WHO guidelines on Core components of infection prevention and
control Programmes. Geneva: World Health Organization; 2018. Available at:
http://www.who.int/infection-prevention/tools/core-components/facility-
manual.pdf?ua=1. Accessed 12 Feb 2019
Zingg et al. Antimicrobial Resistance and Infection Control            (2019) 8:74 Page 5 of 5
